drugset / Trial / NCT05783570
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
NaSingle-groupOpen-labelTreatment
Summary
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 (GPC3) Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have Failed Standard Therapy
Timeline
- Start
- 2023-08-24
- Primary completion
- 2025-06
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EU307 | Cell therapy | — | Intravenous |